About this Journal Submit a Manuscript Table of Contents
Advances in Urology
Volume 2012 (2012), Article ID 181964, 11 pages
http://dx.doi.org/10.1155/2012/181964
Review Article

Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis

1Department of Urology, National Cheng Kung University Hospital, Tainan 70403, Taiwan
2Department of Urology, College of Medicine, National Cheng Kung University, Tainan 70403, Taiwan
3Department of Pathology, College of Medicine, National Cheng Kung University Hospital, Tainan 70403, Taiwan

Received 4 April 2012; Revised 16 May 2012; Accepted 16 May 2012

Academic Editor: Trinity J. Bivalacqua

Copyright © 2012 Yuh-Shyan Tsai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Stenzl, N. C. Cowan, M. De Santis et al., “The updated EAU guidelines on muscle-invasive and metastatic bladder cancer,” European Urology, vol. 55, no. 4, pp. 815–825, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Rouprêt, R. Zigeuner, J. Palou et al., “European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update,” European Urology, vol. 59, no. 4, pp. 584–594, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. C. H. Heldin, “Dimerization of cell surface receptors in signal transduction,” Cell, vol. 80, no. 2, pp. 213–223, 1995. View at Scopus
  4. R. Pinkas-Kramarski, M. Shelly, S. Glathe, B. J. Ratzkin, and Y. Yarden, “Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations,” Journal of Biological Chemistry, vol. 271, no. 32, pp. 19029–19032, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. N. H. Chow, S. H. Chan, T. S. Tzai, C. L. Ho, and H. S. Liu, “Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder,” Clinical Cancer Research, vol. 7, no. 7, pp. 1957–1962, 2001. View at Scopus
  6. S. V. Sharma, D. W. Bell, J. Settleman, and D. A. Haber, “Epidermal growth factor receptor mutations in lung cancer,” Nature Reviews Cancer, vol. 7, no. 3, pp. 169–181, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,” New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. K. I. Pritchard, L. E. Shepherd, F. P. O'Malley et al., “HER2 and responsiveness of breast cancer to adjuvant chemotherapy,” New England Journal of Medicine, vol. 354, no. 20, pp. 2103–2111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Slamon, W. Eiermann, N. Robert et al., “Adjuvant trastuzumab in HER2-positive breast cancer,” The New England Journal of Medicine, vol. 365, no. 14, pp. 1273–1283, 2011.
  10. M. R. Freeman, “HER2/HER3 heterodimers in prostate cancer: whither HER1/EGFR?” Cancer Cell, vol. 6, no. 5, pp. 427–428, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Blackledge, W. R. Sellers, and M. R. Smith, “Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy,” Journal of Urology, vol. 170, no. 6, pp. S77–S83, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Yan, G. L. Andriole, P. A. Humphrey, and A. S. Kibel, “Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors,” Cancer, vol. 95, no. 6, pp. 1239–1246, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Chakravarti, K. Winter, C. L. Wu et al., “Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group,” International Journal of Radiation Oncology Biology Physics, vol. 62, no. 2, pp. 309–317, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Lipponen and M. Eskelinen, “Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis,” British Journal of Cancer, vol. 69, no. 6, pp. 1120–1125, 1994. View at Scopus
  15. D. E. Neal, L. Sharples, K. Smith, J. Fennelly, R. R. Hall, and A. L. Harris, “The epidermal growth factor receptor and the prognosis of bladder cancer,” Cancer, vol. 65, no. 7, pp. 1619–1625, 1990. View at Scopus
  16. W. Kassouf, P. C. Black, T. Tuziak et al., “Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer,” Journal of Urology, vol. 179, no. 1, pp. 353–358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Pich, L. Chiusa, A. Formiconi et al., “Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder,” Cancer, vol. 95, no. 4, pp. 784–790, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Têtu, Y. Fradet, P. Allard, C. Veilleux, N. Roberge, and P. Bernard, “Prevalence and clinical significance of HER-2/neu, p53 and Rb expression in primary superficial bladder cancer,” Journal of Urology, vol. 155, no. 5, pp. 1784–1788, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Ravery, M. Colombel, Z. Popov et al., “Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer,” British Journal of Cancer, vol. 71, no. 1, pp. 196–200, 1995. View at Scopus
  20. Z. Popov, S. Gil-Diez-De-Medina, V. Ravery et al., “Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications,” Urologic Oncology, vol. 22, no. 2, pp. 93–101, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Gallucci, E. Vico, R. Merola et al., “Adverse genetic prognostic profiles define a poor outcome for cystectomy in bladder cancer,” Experimental and Molecular Pathology, vol. 83, no. 3, pp. 385–391, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Gandour-Edwards, P. N. Lara, A. K. Folkins et al., “Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?” Cancer, vol. 95, no. 5, pp. 1009–1015, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Underwood, J. Bartlett, J. Reeves, D. S. Gardiner, R. Scott, and T. Cooke, “C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?” Cancer Research, vol. 55, no. 11, pp. 2422–2430, 1995. View at Scopus
  24. Y. S. Tsai, T. S. Tzai, N. H. Chow et al., “Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan,” Urologia Internationalis, vol. 71, no. 3, pp. 262–270, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Haitel, B. Posch, M. El-Baz et al., “Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2,” Journal of Urology, vol. 165, no. 5 I, pp. 1481–1487, 2001. View at Scopus
  26. H. M. Khaled, A. A. Bahnassy, A. A. Raafat, A. R. N. Zekri, M. S. Madboul, and N. M. Mokhtar, “Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bilharzial bladder cancer,” BMC Cancer, vol. 9, article 32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Liedberg, H. Anderson, G. Chebil et al., “Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail?” Urologic Oncology, vol. 26, no. 1, pp. 17–24, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. A. A. Memon, B. S. Sorensen, P. Meldgaard, L. Fokdal, T. Thykjaer, and E. Nexo, “The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients,” British Journal of Cancer, vol. 94, no. 11, pp. 1703–1709, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. V. B. Thøgersen, B. S. Sørensen, S. S. Poulsen, T. F. Ørntoft, H. Wolf, and E. Nexo, “A subclass of HER1 ligands is a prognostic marker for survival in bladder cancer patients,” Cancer Research, vol. 61, no. 16, pp. 6227–6233, 2001. View at Scopus
  30. U. Lonn, S. Lonn, S. Friberg, B. Nilsson, C. Silfversward, and B. Stenkvist, “Prognostic value of amplification of c-erb-B2 in bladder carcinoma,” Clinical Cancer Research, vol. 1, no. 10, pp. 1189–1194, 1995. View at Scopus
  31. H. Miyamoto, Y. Kubota, S. Noguchi et al., “C-erbB-2 gene amplification as a prognostic marker in human bladder cancer,” Urology, vol. 55, no. 5, pp. 679–683, 2000. View at Scopus
  32. R. Simon, R. Atefy, U. Wagner et al., “HER-2 and TOP2A coamplification in urinary bladder cancer,” International Journal of Cancer, vol. 107, no. 5, pp. 764–772, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. R. E. Jimenez, M. Hussain, F. J. Bianco et al., “Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors,” Clinical Cancer Research, vol. 7, no. 8, pp. 2440–2447, 2001. View at Scopus
  34. S. B. Kolla, A. Seth, M. K. Singh et al., “Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy,” International Urology and Nephrology, vol. 40, no. 2, pp. 321–327, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Krüger, G. Weitsch, H. Büttner et al., “HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications,” International Journal of Cancer, vol. 102, no. 5, pp. 514–518, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Krüger, A. Mahnken, I. Kausch, and A. C. Feller, “Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma,” Urology, vol. 67, no. 1, pp. 105–109, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Sato, M. Moriyama, S. Mori et al., “An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma,” Cancer, vol. 70, no. 10, pp. 2493–2498, 1992. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. L. S. Wong, E. R. Plimack, D. J. Vaughn et al., “Effect of EGFR inhibition with cetuximab on the efficacy of paclitaxel in previously treated metastatic urothelial cancer,” Journal of Clinical Oncology, vol. 29, supplement 7, abstract 243, 2011.
  39. G. K. Philips, S. Halabi, B. L. Sanford, D. Bajorin, and E. J. Small, “A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102,” British Journal of Urology International, vol. 101, no. 1, pp. 20–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. G. K. Philips, S. Halabi, B. L. Sanford, D. Bajorin, and E. J. Small, “A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102,” Annals of Oncology, vol. 20, no. 6, pp. 1074–1079, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. D. P. Petrylak, C. M. Tangen, P. J. Van Veldhuizen et al., “Results: of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium,” British Journal of Urology International, vol. 105, no. 3, pp. 317–321, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Wülfing, J. P. H. Machiels, D. J. Richel et al., “A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma,” Cancer, vol. 115, no. 13, pp. 2881–2890, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. T. K. Choueiri, R. W. Ross, S. Jacobus et al., “Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer,” Journal of Clinical Oncology, vol. 30, no. 5, pp. 507–512, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Heimberg, I. Weinstein, V. S. LeQuire, and S. Cohen, “The induction of fatty liver in neonatal animals by a purified protein (EGF) from mouse submaxillary gland,” Life Sciences, vol. 4, no. 17, pp. 1625–1633, 1965. View at Scopus
  45. S. Cohen, G. Carpenter, and L. King, “Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity,” Journal of Biological Chemistry, vol. 255, no. 10, pp. 4834–4842, 1980. View at Scopus
  46. D. E. Neal, K. Smith, J. A. Fennelly, M. K. Bennett, R. R. Hall, and A. L. Harris, “Epidermal growth factor receptor in human bladder cancer: a comparison of immunohistochemistry and ligand binding,” Journal of Urology, vol. 141, no. 3 I, pp. 517–521, 1989. View at Scopus
  47. N. H. Chow, H. S. Liu, E. I. C. Lee et al., “Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer,” Anticancer Research, vol. 17, no. 2B, pp. 1293–1296, 1997. View at Scopus
  48. A. L. Mattila, J. Perheentupa, K. Pesonen, and L. Viinikka, “Epidermal growth factor in human urine from birth to puberty,” Journal of Clinical Endocrinology and Metabolism, vol. 61, no. 5, pp. 997–1000, 1985. View at Scopus
  49. K. Stromberg, M. Duffy, C. Fritsch et al., “Comparison of urinary transforming growth factor-alpha in women with disseminated breast cancer and healthy control women,” Cancer Detection and Prevention, vol. 15, no. 4, pp. 277–283, 1991. View at Scopus
  50. A. Ullrich and J. Schlessinger, “Signal transduction by receptors with tyrosine kinase activity,” Cell, vol. 61, no. 2, pp. 203–212, 1990. View at Publisher · View at Google Scholar · View at Scopus
  51. M. A. Lemmon and J. Schlessinger, “Cell signaling by receptor tyrosine kinases,” Cell, vol. 141, no. 7, pp. 1117–1134, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. M. A. Olayioye, R. M. Neve, H. A. Lane, and N. E. Hynes, “The ErbB signaling network: receptor heterodimerization in development and cancer,” EMBO Journal, vol. 19, no. 13, pp. 3159–3167, 2000. View at Scopus
  53. M. A. Olayioye, D. Graus-Porta, R. R. Beerli, J. Rohrer, B. Gay, and N. E. Hynes, “ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner,” Molecular and Cellular Biology, vol. 18, no. 9, pp. 5042–5051, 1998. View at Scopus
  54. J. Yoshida, T. Ishibashi, and M. Nishio, “Growth-inhibitory effect of a streptococcal antitumor glycoprotein on human epidermoid carcinoma A431 cells: involvement of dephosphorylation of epidermal growth factor receptor,” Cancer Research, vol. 61, no. 16, pp. 6151–6157, 2001. View at Scopus
  55. X. B. Qiu and A. L. Goldberg, “Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 23, pp. 14843–14848, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. H. A. J. Alwan, E. J. J. Van Zoelen, and J. E. M. Van Leeuwen, “Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination,” Journal of Biological Chemistry, vol. 278, no. 37, pp. 35781–35790, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. P. O. Hackel, E. Zwick, N. Prenzel, and A. Ullrich, “Epidermal growth factor receptors: critical mediators of multiple receptor pathways,” Current Opinion in Cell Biology, vol. 11, no. 2, pp. 184–189, 1999. View at Publisher · View at Google Scholar · View at Scopus
  58. J. L. Marks, M. McLellan, M. F. Zakowski et al., “Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4,” PLoS ONE, vol. 2, no. 5, article e426, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. Nieto, F. Nawaz, R. B. Jones, E. J. Shpall, and S. Nawaz, “Prognostic significance of overexpression and phosphorylation of Epidermal Growth Factor Receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer,” Journal of Clinical Oncology, vol. 25, no. 28, pp. 4405–4413, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. L. A. Akslen, H. Puntervoll, I. M. Bachmann et al., “Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma,” Melanoma Research, vol. 18, no. 1, pp. 29–35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Peraldo-Neia, G. Migliardi, M. Mello-Grand et al., “Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer,” BMC Cancer, vol. 11, article 31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. Z. Latif, A. D. Watters, I. Dunn, K. M. Grigor, M. Underwood, and J. Bartlett, “HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder,” British Journal of Cancer, vol. 89, no. 7, pp. 1305–1309, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Avraham and Y. Yarden, “Feedback regulation of EGFR signalling: decision making by early and delayed loops,” Nature Reviews Molecular Cell Biology, vol. 12, no. 2, pp. 104–117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. D. Amsellem-Ouazana, P. Beuzeboc, M. Peyromaure, A. Viellefond, M. Zerbib, and B. Debre, “Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression,” Annals of Oncology, vol. 15, no. 3, p. 538, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. S. Tsai, T. S. Tzai, and N. H. Chow, “Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?” Urologia Internationalis, vol. 79, no. 3, pp. 210–216, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. P. Puppo, G. Conti, F. Francesca, A. Mandressi, and A. Naselli, “New Italian guidelines on bladder cancer, based on the World Health Organization 2004 classification,” British Journal of Urology International, vol. 106, no. 2, pp. 168–179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Stenzl, N. C. Cowan, M. De Santis et al., “Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines,” European Urology, vol. 59, no. 6, pp. 1009–1018, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Laupacis, G. Wells, W. S. Richardson et al., “Users' guides to the medical literature: V. How to use an article about prognosis,” Journal of the American Medical Association, vol. 272, no. 3, pp. 234–237, 1994. View at Publisher · View at Google Scholar · View at Scopus
  69. N. Malats, A. Bustos, C. M. Nascimento et al., “P53 as a prognostic marker for bladder cancer: a meta-analysis and review,” Lancet Oncology, vol. 6, no. 9, pp. 678–686, 2005. View at Publisher · View at Google Scholar · View at Scopus